NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month
The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
Pierre Fabre Laboratories Announces Global Partnership with Know Your Lemons Foundation for Breast Cancer Awareness Month
Innovative Campaign Focuses on Early Detection and Empowering Education Throughout October CASTRES,…
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN),…
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX),…
Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for…
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY (Piflufolastat F 18) in Japan
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) --…
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICSÂ (Nasdaq: SOPH), an AI technology…
New mobile units to drive early breast cancer detection in Alberta
EDMONTON, Alberta, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Breast cancer screening is…
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…